Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Feasibility Study of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04147884
Recruitment Status : Recruiting
First Posted : November 1, 2019
Last Update Posted : September 17, 2020
Sponsor:
Information provided by (Responsible Party):
Boston Scientific Corporation

Brief Summary:
To evaluate the feasibility and safety of the Millipede Transcatheter Annuloplasty Ring System (Millipede System) in patients with functional mitral regurgitation

Condition or disease Intervention/treatment Phase
Mitral Regurgitation Functional Mitral Valve Disease Cardiovascular Diseases Device: Millipede Transcatheter Annuloplasty Ring System (Millipede System) Not Applicable

Detailed Description:
The Millipede Feasibility Study is a prospective, open-label, single-arm study to assess the safety and feasibility of the Millipede Transcatheter Annuloplasty Ring System in patients with functional mitral regurgitation. The study will include subjects with functional mitral regurgitation classified as moderate to severe (3+) or severe (4+) that are symptomatic (NYHA Class II-IV) despite guideline directed medical therapy in whom the local hearth team determines that surgery is not an option for mitral valve repair. Clinical follow-up will be required in hospital, 30 days, 90 days, 6 months, 12 months, and then annually through 5 years post-procedure. Subjects who have any part of the Millipede Transcatheter Annuloplasty Ring System introduced into the body but who do not end up with an implant will be followed through 30 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Device Feasibility
Official Title: A Study to Evaluate the Feasibility and Safety of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation: (Millipede Feasibility Study)
Actual Study Start Date : November 13, 2019
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Arm Intervention/treatment
Experimental: Mitral Valve Repair
All subjects will receive mitral valve repair using the Millipede System
Device: Millipede Transcatheter Annuloplasty Ring System (Millipede System)
The Millipede Transcatheter Annuloplasty Ring System is a repair device used for treating mitral valve regurgitation (MR). The system consists of several components: a transcatheter annuloplasty ring (implant) which remains in the body and a delivery system and intracardiac echocardiography catheter (imaging device) used to deliver the implant to the mitral valve.




Primary Outcome Measures :
  1. Technical Success [ Time Frame: Discharge or 7 days post-procedure, whichever comes ]
    Technical Success is defined as successful delivery of the device in the correct anatomical position and withdrawal of the delivery system without conversion to surgery or in-hospital mortality



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is 18 years of age or older
  • Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed
  • Subject has moderate to severe (3+) or severe (4+) functional mitral regurgitation
  • Subject is symptomatic (NYHA Class II-IV) despite guideline directed medical therapy, including CRT if indicated
  • The local site heart team concurs that surgery will not be offered as a treatment option
  • Subject is a candidate for annuloplasty based on the criteria below as assessed by the investigative site:

Left Ventricular Ejection Fraction (LVEF) ≥ 25% Left Ventricular End Diastolic Diameter (LVEDD) ≤ 65 mm Coaptation distance (i.e. tenting height) < 10 mm Absence of posterior wall aneurysm

Exclusion Criteria:

  • Subject has severe calcification of the mitral annulus or leaflets, mitral annular diameter >43 mm in any dimension or other anatomic features which make the patient unsuitable for annuloplasty with the Millipede System in the judgment of the treating physician
  • Transfemoral venous and transseptal access determined not to be feasible
  • Subject is on the waiting list for a transplant or has had a prior heart transplant
  • Subject has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 30 days prior to study enrollment
  • Subject has had any percutaneous coronary, carotid, or other endovascular intervention within 30 days prior to study enrollment
  • Subject has had carotid surgery within 30 days prior to study enrollment
  • Subject has had any open coronary or vascular surgery (other than carotid surgery) within 3 months prior to study enrollment
  • Subject has had a cardiac resynchronization therapy (CRT) device implantation within 3 months prior to study enrollment
  • Subject has untreated clinically significant coronary artery disease requiring revascularization
  • Any planned cardiac surgery within the next 12 months
  • Need for emergent or urgent surgery for any reason
  • Subject has severe aortic valve stenosis and/or aortic valve regurgitation
  • Subject has physical evidence of right-sided congestive heart failure (CHF) with echocardiographic evidence of moderate or severe right ventricular dysfunction and/or severe tricuspid valve regurgitation
  • Subject has the presence of prosthetic heart valve in any position
  • Subject has renal insufficiency requiring dialysis
  • Subject has a life expectancy less than 12 months
  • Subjects in whom trans-esophageal ECHO/Doppler is contraindicated or in which mitral regurgitation is not measurable by Transthoracic Echocardiography (TTE)
  • Subject has known hypersensitivity or contraindication to protocol required procedural or post procedural medication (e.g., anticoagulation therapy) or hypersensitivity to nickel or titanium
  • Subject has known hypersensitivity to contrast that cannot be adequately premedicated

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04147884


Contacts
Layout table for location contacts
Contact: Blessie Concepcion 800-876-9960 Blessie.Concepcion@bsci.com
Contact: Alison Osattin 800-876-9960 alison.osattin@bsci.com

Locations
Layout table for location information
Australia, Victoria
Monash Medical Centre Recruiting
Clayton, Victoria, Australia, 3168
Contact: Robert Gooley, MBBS    61 3 9594 2726    Robert.Gooley@monashhealth.org   
Principal Investigator: Robert Gooley, MBBS         
The Alfred Hospital Recruiting
Melbourne, Victoria, Australia, 3004
Contact: Anthony Walton, MBBS    0414332444    twalton93@me.com   
Contact: MBBS         
Principal Investigator: Anthony Walton, MBBS         
Sponsors and Collaborators
Boston Scientific Corporation
Investigators
Layout table for investigator information
Principal Investigator: Robert Gooley, MBBS Monash Health
Layout table for additonal information
Responsible Party: Boston Scientific Corporation
ClinicalTrials.gov Identifier: NCT04147884    
Other Study ID Numbers: S2436
First Posted: November 1, 2019    Key Record Dates
Last Update Posted: September 17, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: The data and study protocol for this clinical trial may be made available to other researchers in accordance with the Boston Scientific Data Sharing Policy (http://www.bostonscientific.com/en-US/data-sharing-requests.html)

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Boston Scientific Corporation:
Functional Mitral Regurgitation
Mitral Repair
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases
Mitral Valve Insufficiency
Heart Valve Diseases
Heart Diseases